ABBOTT LABORATORIES Income (Loss) from Continuing Operations before Income Taxes, Domestic
ABBOTT LABORATORIES (ABT) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of $1.76 billion for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-20.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-02-20
- ABBOTT LABORATORIES income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was $1.76B, a 86.06% increase from fiscal 2024.
- ABBOTT LABORATORIES income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was $947.00M, a 20.55% decline from fiscal 2023.
- ABBOTT LABORATORIES income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was $1.19B, a 68.06% decline from fiscal 2022.
- ABBOTT LABORATORIES income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was $3.73B, a 14.34% increase from fiscal 2021.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month as first filed |
|---|---|---|
| 2025-12-31 | $1.76B 10-K · filed 2026-02-20 | |
| 2024-12-31 | $947.00M 10-K · filed 2026-02-20 | |
| 2023-12-31 | $1.19B 10-K · filed 2026-02-20 | |
| 2022-12-31 | $3.73B 10-K · filed 2025-02-21 | |
| 2021-12-31 | $3.26B 10-K · filed 2024-02-16 | |
| 2020-12-31 | $1.59B 10-K · filed 2023-02-17 | |
| 2019-12-31 | $889.00M 10-K · filed 2022-02-18 | |
| 2018-12-31 | -$430.00M 10-K · filed 2021-02-19 | |
| 2017-12-31 | $308.00M 10-K · filed 2020-02-21 | |
| 2016-12-31 | $306.00M 10-K · filed 2019-02-22 | |
| 2015-12-31 | $789.00M 10-K · filed 2018-02-16 | |
| 2014-12-31 | $392.00M 10-K · filed 2017-02-17 | |
| 2013-12-31 | $496.00M 10-K · filed 2016-02-19 | $529.00M 10-K · filed 2014-02-21 |
| 2012-12-31 | -$1.58B 10-K · filed 2015-02-27 | -$620.00M 10-K · filed 2013-02-15 |
| 2011-12-31 | -$593.00M 10-K · filed 2014-02-21 | $364.00M 10-K · filed 2012-02-21 |
| 2010-12-31 | -$275.00M 10-K · filed 2013-02-15 | |
| 2009-12-31 | $1.50B 10-K · filed 2012-02-21 | |
| 2008-12-31 | -$81.00M 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |